Octreotide Injection

342 interactions 555 cited references
Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot
About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone
13 Contraindicated 325 Major 4 Moderate
All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Trimethoprim Primsol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Trimipramine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Triptorelin Increased risk of QT interval prolongation Details Octreotide Injection Vandetanib Caprelsa Increased risk of QT interval prolongation Details Octreotide Injection Vardenafil Levitra An increased risk of QT interval prolongation Details Octreotide Injection Vemurafenib Zelboraf Increased risk of QT interval prolongation Details Octreotide Injection Venlafaxine An increased risk of QT interval prolongation Details Octreotide Injection Vepdegestrant Veppanu An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, ot... Details Octreotide Injection Vilanterol An increased risk of QT interval prolongation Details Octreotide Injection Vildagliptin An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Vinflunine Increased risk of QT-interval prolongation Details Octreotide Injection Voclosporin Lupkynis An increased risk of QT interval prolongation Details Octreotide Injection Voriconazole Vfend An increased risk of QT interval prolongation Details Octreotide Injection Zanubrutinib Brukinsa Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Ziftomenib Komzifti An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Zolmitriptan Zomig An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Zotepine An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Octreotide Injection Zuclopenthixol An increased risk of QT interval prolongation Details

Moderate

Octreotide Injection Bromocriptine Cycloset Increased bromocriptine exposure Details Octreotide Injection Lisinopril Prinivil Increased lisinopril bioavailability Details Octreotide Injection Pegvisomant Elevated liver enzymes Details Octreotide Injection Telotristat Ethyl Xermelo Decreased exposure to telotristat ethyl Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.